电针预刺激对腹腔镜前列腺癌根治切除术老年患者术后谵妄的影响:一项双中心、前瞻性、双盲、随机对照实验

注册号:

Registration number:

ITMCTR2024000490

最近更新日期:

Date of Last Refreshed on:

2024-09-26

注册时间:

Date of Registration:

2024-09-26

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

电针预刺激对腹腔镜前列腺癌根治切除术老年患者术后谵妄的影响:一项双中心、前瞻性、双盲、随机对照实验

Public title:

Effect of Prestimulationon of Electroacupuncture on Postoperative Delirium in Elderly Patients undergoing Laparoscopic Radical ProstatectomyA Double-centerprospectivedouble-blindrandomizedcontrolled trail

注册题目简写:

English Acronym:

研究课题的正式科学名称:

电针预刺激对腹腔镜前列腺癌根治切除术老年患者术后谵妄的影响:一项双中心、前瞻性、双盲、随机对照实验

Scientific title:

Effect of Prestimulationon of Electroacupuncture on Postoperative Delirium in Elderly Patients undergoing Laparoscopic Radical ProstatectomyA Double-centerprospectivedouble-blindrandomizedcontrolled trail

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

魏世荣

研究负责人:

倪华栋

Applicant:

Shirong Wei

Study leader:

Huadong Ni

申请注册联系人电话:

Applicant telephone:

+86 156 7061 7156

研究负责人电话:

Study leader's telephone:

+86 150 6838 6387

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15670617156@163.com

研究负责人电子邮件:

Study leader's E-mail:

huadongni@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

浙江省嘉兴市南湖区中环南路1882号嘉兴市第一医院

研究负责人通讯地址:

浙江省嘉兴市南湖区中环南路1882号嘉兴市第一医院

Applicant address:

Jiaxing First Hospital 1882 Zhonghuan Road South Nanhu District Jiaxing Zhejiang

Study leader's address:

Jiaxing First Hospital 1882 Zhonghuan Road South Nanhu District Jiaxing Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

嘉兴市第一医院

Applicant's institution:

Jiaxing First Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024-LY-611

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

嘉兴市第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Jiaxing First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/7/30 0:00:00

伦理委员会联系人:

钱建萍

Contact Name of the ethic committee:

Jianping Qian

伦理委员会联系地址:

嘉兴市中环南路1882号嘉兴市第一医院行政楼3楼

Contact Address of the ethic committee:

Floor 3 Administration Building Jiaxing First Hospital 1882 Zhonghuan Road South Nanhu District Jiaxing Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 573 8997 6378

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1276408212@qq.com

研究实施负责(组长)单位:

嘉兴市第一医院

Primary sponsor:

Jiaxing First Hospital

研究实施负责(组长)单位地址:

浙江省嘉兴市南湖区中环南路1882号嘉兴市第一医院

Primary sponsor's address:

Jiaxing First Hospital 1882 Zhonghuan Road South Nanhu District Jiaxing Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

嘉兴市

Country:

China

Province:

Zhejiang province

City:

Jiaxing

单位(医院):

嘉兴市第一医院

具体地址:

嘉兴市中环南路1882号

Institution
hospital:

Jiaxing First Hospital

Address:

No. 1882 Zhonghuan South Road Jiaxing City China

经费或物资来源:

自费

Source(s) of funding:

Self-funded

研究疾病:

术后谵妄

研究疾病代码:

Target disease:

Postoperative delirium

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

我们设计了一项前瞻性、双中心、平行组、随机对照试验,研究电针 ST36、GV20是否能降低老年泌尿外科手术患者术后谵妄的发生率。此外,我们打算确定电针在老年腹腔镜前列腺癌根治术患者术后谵妄的影响

Objectives of Study:

we have devised a prospective double-centre parallel-group randomized controlled trial aimed at assessing the efficacy of electroacupuncture at ST36 GV20 in reducing the incidence of POD in elderly patients undergoing Laparoscopic Radical Prostatectomy.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)行全身麻醉下腹腔镜根治性前列腺切除术(RP)的患者 ;2)参与者年龄在 65 岁及以上;3)纳入美国麻醉医师学会(ASA)身体状态分类为 I ~ III 的参与者;4)参与者愿意提供书面知情同意书;5)参与者意识清晰,沟通能力正常

Inclusion criteria

1) patients undergoing laparoscopic radical prostatectomy (RP) under general anesthesia 2) participants aged 65 years or older 3) participants with American Society of Anesthesiologists (ASA) physical status class I-III were included 4) the participants are willing to provide written informed consent 5) Participants were conscious and had normal communication skills.

排除标准:

标准 :1)有穴位感染的患者;2)认知障碍、痴呆患者; 3)不稳定的冠心病;4)肾脏系统疾病(估计肾小球滤过率<30mL/min/1.73 m2);5)肝脏系统疾病(谷丙转氨酶或谷草转氨酶大于正常值的两倍);6)凝血功能障碍(凝血酶原时间或活化部分凝血活酶时间高于正常界值)或因其他疾病原因正在口服且术前未停用华法林、新型抗凝药如利伐沙班、达比加群的患者;7)过去 6 个月内有酒精、药物依赖或精神疾病治疗史,如精神分裂症、严重焦虑、抑郁等; 8)可能导致认知障碍的脑结构性病变史,如外伤性脑损伤、中风、颅内占位性病变、先天性智力低下等; 9)患者同时参与其他临床试验;

Exclusion criteria:

1) patients with acupoint infection; 2) patients with cognitive impairment or dementia; 3) unstable coronary artery disease; 4) renal disease (estimated glomerular filtration rate <30mL/min/1.73 m2); 5) liver disease (alanine aminotransferase or aspartate aminotransferase > twice the normal value); 6) patients with coagulopathy (prothrombin time or activated partial thromboplastin time higher than the normal limit) or oral warfarin new anticoagulants such as rivaroxaban and dabigatran were not stopped before operation due to other diseases; 7) a history of treatment for alcohol or drug dependence or psychiatric disorders (e.g. schizophrenia severe anxiety depression etc.) in the past 6 months; 8) history of structural brain lesions that may lead to cognitive impairment such as traumatic brain injury stroke intracranial space occupying lesions congenital mental retardation etc.; 9) patients participating in other clinical trials;

研究实施时间:

Study execute time:

From 2024-08-01

To      2026-08-30

征募观察对象时间:

Recruiting time:

From 2024-08-01

To      2026-08-30

干预措施:

Interventions:

组别:

假电针组

样本量:

106

Group:

Sham-electroacupuncture group

Sample size:

干预措施:

假电针

干预措施代码:

Intervention:

Sham-electroacupuncture

Intervention code:

组别:

电针组

样本量:

106

Group:

Electroacupuncture group

Sample size:

干预措施:

电针

干预措施代码:

Intervention:

Electroacupuncture

Intervention code:

样本总量 Total sample size : 212

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江

市(区县):

嘉兴市

Country:

China

Province:

Zhejiang province

City:

Jiaxing

单位(医院):

嘉兴市第一医院

单位级别:

三甲

Institution/hospital:

Jiaxing First Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

谵妄的发作时间和持续时间

指标类型:

次要指标

Outcome:

Onset time and duration of delirium

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血液检查指标

指标类型:

次要指标

Outcome:

Blood test indexes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阿片类物质消耗量

指标类型:

次要指标

Outcome:

Opioid consumption

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谵妄严重程度评分

指标类型:

次要指标

Outcome:

Delirium severity score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

Pain scores

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期焦虑评分

指标类型:

次要指标

Outcome:

Perioperative anxiety score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导尿管相关性膀胱不适的发生率和严重程度

指标类型:

次要指标

Outcome:

Incidence and severity of catheter-related bladder discomfort

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谵妄发作次数

指标类型:

次要指标

Outcome:

Number of POD episodes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谵妄的亚型

指标类型:

次要指标

Outcome:

Subtypes of delirium

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后谵妄发生率

指标类型:

主要指标

Outcome:

the incidence of postoperative delirium

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 65
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

统计学家将使用 SPSS 软件版本 25.0 生成与 EA 组或对照组的 1:1 比例的随机数表。随机数将根据计算机生 成的表格进行,数据块大小为 4。随机化过程将由不参与研究的独立统计学家执行,以确保分配无偏,不受潜 在混杂因素的影响。随机化是研究设计的关键组成部分,因为它有助于最大限度地减少选择偏差,并确保组间 观察到的任何差异都归因于所研究的干预措施。通过利用计算机化随机化过程和独立的个人来执行分配,我们 的目标是确保我们的研究以最高水平的科学严谨性和完整性进行。

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization procedure will be conducted using SPSS software version 25.0 which will generate a random number table maintaining a 1:1 allocation ratio between the electroacupuncture (EA) group and the control group. The randomization will be performed with a block size of 4 facilitated by a statistician not directly involved in the study. This approach aims to ensure an unbiased allocation process mitigating potential confounding variables. Randomization stands as a pivotal aspect of the study design essential for minimizing selection bias and attributing any observed differences between groups to the intervention under investigation. Employing computerized randomization overseen by an independent expert enhances the scientific rigor and integrity of our study

盲法:

在整个试验过程中,除了针灸师外,没有人被告知具体的干预措施,在签署知情同意书时,受试者被简单地告 知被分配到 EA 组或 SEA 组的相同机会。此外,分析统计学家和术后随访工作人员将对分组分配进行盲法处 理,以确保数据分析是公正的,不受潜在混杂因素来源的影响。

Blinding:

Throughout the trial apart from the acupuncturist all involved parties remained uninformed regarding the specific intervention. Participants were simply informed of an equal opportunity to be assigned to either the electroacupuncture (EA) group or the sham electroacupuncture (SEA) group upon signing the informed consent. Furthermore the statisticians conducting data analysis and the postoperative follow-up staff will be blinded to group allocation thereby safeguarding against bias and minimizing potential confounding factors in the data analysis process

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Resman

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),使用ResMan作为基于互联网的EDC。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data capture and management consists of two parts Case Record Form (CRF) and Electronic Data Capture (EDC) using ResMan as the Internet-based EDC.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统